The key paramete r for any drug product is its efficacy as demonstrated in con- 
Introduction
]Jl Mlly 1997, FDA ,"elensed a guidallce entitled Scale-up aJld P ost Approval C hanges: C hemistry, MaJlufacturin g and Contro ls, In Vitro Release -restin g and In Vivo Bioequi va lence Docum entation fo r No nsterile SemisoLid Dosage Fonns (SUPA C-SS) (I). Tbe gu idallce focuses 011 nonxterile semisolid dosage forms sllch flS creams, gels, lotions, find ointments. Tbe document describes allO'lvllble cbanges ill fom' Sepfl1"flte mtegories, as follows: J) c07llpolle1lfs IIlld composition; 2) 'I1Ifl11l1fi'ctlwing equipment 1I1lt! process; 3) sCllle (botcb size); and 4) site of 'IIlll1ll1foct'll1"f:. Cbo1Jges nre categorized liS Level J, Level 2 /Iud Level 3, depending 011 fbe degree of cb/lnge lIud tbe type of tests lleeded to document comparability;l1 identity, strengtb, qUlllity, p1l1"ity, IIlId potency oftbe drug product bejore lind lifter tbe chllnge. L,'Vel 1 cbollges are tbose tbat lire unlikely to bave tll1Y detectable impact on-formulation quality aud pe,jonllal1ce of the produd.. This degree of change does 110t 1'equire Imy additional testing for prodlld approval beyond assurance tbllt application and compendial speciftClltiol1S are lIIet.
Lroel 2 changes are tbose that could have a signijica71l impact on fl17l1 l1latioll quality alld perfo17l1al1ce oftbe product. FOl' Lroel2 chllnges, the guidance 1'ecommeuds in vitro release (lVR) testing in addition to flJ1'IITing thllt application and comp(!lIdial Jpeciftcatio71S are 'IIIet. Lroel3 changes are those tbat are likely to have n significant impllct 011 jorlllulllfioll qUlllity and pe1'-fonJlfl11ce of the product. This degree of change requh-es in vitro release test for a site cbllllge or in vivo bioequivalel1ce testing for cbonges in component IIlId composition, ill additiol1 to assurance that application and compendial specifications m'e met.
~"
ey aspect of the SUPAC-SS document is the recommendation that in vitro release testing be used under certa in circumstances. If the tes t is not passed at th e first stage, 4 additional runs of the (six cells) in vitro apparatus should be carried out, yielding 12 additio nal slopes fo r each produ ct, o r 18 in all (includin g the first-stage res ults). T he 90% confidence inte r va l (describ ed o n page 10) s ho uld be co mpu ted usin g all 18 slopes fo r each product, including the first-stage resul ts. At the second stage, thi s 90% confid ence in terval should fall within the limi ts of75 % to 133.33 % .
continued on pllge J 0 Application of In Vitro Release Methods ... cont.
Computation of Confidence
Interval -an Example:
• Because outliers are expected to occur on occasion with this testing (for example, due to an air bubble between the product sample and the membrane), a nonparameoic method is proposed, whose perfonnance tends to be resistant to the presence of outliers. The first step in the computation of the confidence interval is to form the 36 (= 6 x 6) individual T/R ratios. T his is illustrated in the fo ll owi ng table, where the prechange lot slopes O~) are li sted across the top of ti,e table, the postchange lot slopes (I"") are listcd down the left margin of the tab le, and the individua l T/R ratios arc the entries in the body of ti,e table:
1.2863, 1.2945, 1.2964, 1.3190, 1.3551,1.3808,1.4090,1.4357 . In th e third step, the eigbtb and tweuty-ninth ordered individual ratios are th e lower and upper limits, respectively, of the 90% confidence interval for the ratio of the median in vitro release rate (slope) for T over ti,e median in vitro release rate for R. In the example, this con fid ence interval is 1.0343 to 1.2863, or in percentage terms, 103.43% to 128.63%.
Because this co nfid ence interva l falls within the limits of 75% to 133 .33%, the product passes at the first stage.
[f the product had not passed at th e first stage, an additiona l 4 runs would have been carried out, yieldi ng 12 additional slopes per lot, for a total of 18 slopes per lot a ltogether (including the firststage slo pes).
All 324 (= 18 x 18) individual T/R ratios wou ld be obtained, and these wou ld be ranked from lowest to hi ghest. It should be evident that even the compu tations at the first stage would be tedious to do by hand, and doing the computatio ns at the second stage by hand is infeasible . A co mpute r , --------------------------, should be used. its, respectively, of the 90% confidence interva l for the ratio of the median in vitro release rate (slope) for T over the median in vitro release rate for R. ff this confidence interva l falls within the limits of75% to 133.33%, the product passes the test at the seco nd stage.
Further Remarks on d,e In Vitro Release

Coml>arison Test
• The statistica l test described above is based on a st.1ndard confidence interval procedure related to the Wilcoxon Rank Sum/Man n-Whitney rank test, applied to the log slopes (ll, 12). However, as was seen in the example, it is not necessary to actt,ally comp ute logs in order to carry o ut the test.
• The exa mple illustrates the case of fuji data, i.e., where there are 6 slopes per lot at the first stage and , if the second stage is necessary, 18 slopes per lot at th e second stage. If slopes are Inissing, the computations will need to be modified. For exampl e, if a single slope were missing from one of the lots (it does not matter if it is the prechange lot or the postchange lot) at the first stage, there would o nl y be 30 (= 5 x 6) individual TIR ratios, and the limits of the 90% confidence interva l would no longer be ti,e eighth and twenty-ninth o rdered individual T/R ratio, but rather would be the sixth and twenty-fifth ordered individual T/R ratio. [f data are missing at eith er stage of the test, the co rrect computation should be determined by reference to a statistica l text.
• The statistica l procedure as described above docs not take the blockstrucrure of the test (i.e., the fact tl13t data are obtained in runs of six slopes ata time, rather ci'31' all at once) into account. This is justified by ti,e following:
1. Tn vitro re lease data availab le to the Center at this time show no evidence of an important run-tO-fun effect.
2. The proposed experimental des ign, in which both products are included in each rWl , will help to ensure unbiased results if a rUIl-to-fun effect should occur.
Conclusion
The in vin-a re lease procedure is described that can be used to provide assurance of pnxluct sameness between approved prechange and postchange topica l dosage fonns such as creams, gels, lotions and o intm ents.
